Abstract
A set of 20 nucleoside analogs were examined for their inhibitory effects on the cytopathogenicity and growth of influenza virus type A, B, and C strains in Madin-Darby canine kidney (MDCK) cells. Among the compounds evaluated, pyrazofurin, 3-deazaguanine, ribavirin, carbodine, and cyclopentenyl cytosine inhibited viral cytopathogenicity at concentrations that were lower than those found cytotoxic for the MDCK cells. No differences were observed in the 50% effective doses (based on inhibition of viral cytopathogenicity) of these five compounds for a number of influenza virus type A (subtypes H1N1 and H3N2), B, and C strains. Pyrazofurin showed the lowest 50% effective dose (0.15 microgram/ml), which was about 20- to 30-fold lower than those of the other four compounds. The selectivity indices of the five compounds, calculated as the ratio of the 50% cytotoxic dose (determined by trypan blue exclusion) to the 50% effective dose, were greater than 100. When the selectivity indices were calculated as the ratios of the 50% inhibitory doses for cellular RNA synthesis to the 50% effective doses, they were greater than 100 for ribavirin, pyrazofurin, and 3-deazaguanine but less than 2 for carbodine and cyclopentenyl cytosine. All five compounds inhibited the growth of influenza virus types A and B in MDCK cells at a concentration which was well below their cytotoxicity threshold for MDCK cells and, therefore, deserve further exploration for their potential in the treatment of influenza virus type A, B, and C infections.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Allen L. B., Huffman J. H., Dan Cook P., Meyer R. B., Jr, Robins R. K., Sidwell R. W. Antiviral activity of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid. Antimicrob Agents Chemother. 1977 Jul;12(1):114–119. doi: 10.1128/aac.12.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Benoit Y., Laureys G., Delbeke M. J., De Clercq E. Oral BVDU treatment of varicella and zoster in children with cancer. Eur J Pediatr. 1985 Jan;143(3):198–202. doi: 10.1007/BF00442138. [DOI] [PubMed] [Google Scholar]
- Browne M. J. Mechanism and specificity of action of ribavirin. Antimicrob Agents Chemother. 1979 Jun;15(6):747–753. doi: 10.1128/aac.15.6.747. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eriksson B., Helgstrand E., Johansson N. G., Larsson A., Misiorny A., Norén J. O., Philipson L., Stenberg K., Stening G., Stridh S. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother. 1977 Jun;11(6):946–951. doi: 10.1128/aac.11.6.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goswami B. B., Borek E., Sharma O. K., Fujitaki J., Smith R. A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun. 1979 Aug 13;89(3):830–836. doi: 10.1016/0006-291x(79)91853-9. [DOI] [PubMed] [Google Scholar]
- Gutowski G. E., Sweeney M. J., DeLong D. C., Hamill R. L., Gerzon K., Dyke R. W. Biochemistry and biological effects of the pyrazofurins (pyrazomycins): initial clinical trial. Ann N Y Acad Sci. 1975 Aug 8;255:544–551. doi: 10.1111/j.1749-6632.1975.tb29257.x. [DOI] [PubMed] [Google Scholar]
- Hall C. B., Walsh E. E., Hruska J. F., Betts R. F., Hall W. J. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA. 1983 May 20;249(19):2666–2670. [PubMed] [Google Scholar]
- Huffman J. H., Sidwell R. W., Khare G. P., Witkowski J. T., Allen L. B., Robins R. K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kawana F., Shigeta S., Hosoya M., Suzuki H., De Clercq E. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother. 1987 Aug;31(8):1225–1230. doi: 10.1128/aac.31.8.1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McClung H. W., Knight V., Gilbert B. E., Wilson S. Z., Quarles J. M., Divine G. W. Ribavirin aerosol treatment of influenza B virus infection. JAMA. 1983 May 20;249(19):2671–2674. [PubMed] [Google Scholar]
- Monto A. S., Gunn R. A., Bandyk M. G., King C. L. Prevention of Russian influenza by amantadine. JAMA. 1979 Mar 9;241(10):1003–1007. [PubMed] [Google Scholar]
- Oxford J. S. Inhibition of the replication of influenza A and B viruses by a nucleoside analogue (ribavirin). J Gen Virol. 1975 Sep;28(3):409–414. doi: 10.1099/0022-1317-28-3-409. [DOI] [PubMed] [Google Scholar]
- Shannon W. M., Arnett G., Westbrook L., Shealy Y. F., O'Dell C. A., Brockman R. W. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses. Antimicrob Agents Chemother. 1981 Dec;20(6):769–776. doi: 10.1128/aac.20.6.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sidwell R. W., Huffman J. H., Call E. W., Alaghamandan H., Cook P. D., Robins R. K. Activity of selenazofurin against influenza A and B viruses in vitro. Antimicrob Agents Chemother. 1985 Sep;28(3):375–377. doi: 10.1128/aac.28.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
- Streeter D. G., Koyama H. H. Inhibition of purine nucleotide biosynthesis by 3-deazaguanine, its nucleoside and 5'-nucleotide. Biochem Pharmacol. 1976 Nov 1;25(21):2413–2415. doi: 10.1016/0006-2952(76)90041-1. [DOI] [PubMed] [Google Scholar]
- Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robins R. K., Simon L. N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174–1178. doi: 10.1073/pnas.70.4.1174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Van Voris L. P., Betts R. F., Hayden F. G., Christmas W. A., Douglas R. G., Jr Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981 Mar 20;245(11):1128–1131. doi: 10.1001/jama.245.11.1128. [DOI] [PubMed] [Google Scholar]
- Wade J. C., Newton B., McLaren C., Flournoy N., Keeney R. E., Meyers J. D. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med. 1982 Mar;96(3):265–269. doi: 10.7326/0003-4819-96-3-265. [DOI] [PubMed] [Google Scholar]
- Whitley R. J., Soong S. J., Dolin R., Galasso G. J., Ch'ien L. T., Alford C. A. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. 1977 Aug 11;297(6):289–294. doi: 10.1056/NEJM197708112970601. [DOI] [PubMed] [Google Scholar]
- Wilson S. Z., Gilbert B. E., Quarles J. M., Knight V., McClung H. W., Moore R. V., Couch R. B. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 1984 Aug;26(2):200–203. doi: 10.1128/aac.26.2.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wray S. K., Gilbert B. E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 1985 Feb;5(1):39–48. doi: 10.1016/0166-3542(85)90013-0. [DOI] [PubMed] [Google Scholar]
- Wray S. K., Smith R. H., Gilbert B. E., Knight V. Effects of selenazofurin and ribavirin and their 5'-triphosphates on replicative functions of influenza A and B viruses. Antimicrob Agents Chemother. 1986 Jan;29(1):67–72. doi: 10.1128/aac.29.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]